Compare Agilent Technologies Inc (A) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Agilent Technologies Inc vs Moderna, Inc. — how do they compare? Agilent Technologies Inc trades at $149.5 (market cap $42.22B), while Moderna, Inc. trades at $60.5 (market cap $24.18B). The key difference: Agilent Technologies Inc is the larger of the two by market cap, and Agilent Technologies Inc pays a 0.68% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| A | MRNA | |
|---|---|---|
Market Cap | $42.22B | $24.18B |
Sector | Health | Health |
52-Week High | $157.20 | $81.80 |
52-Week Low | $110.24 | $22.36 |
Enterprise Value | $43.77B | $20.33B |
Dividend Yield | 0.68% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
